EMA Urges Quick Communication on Drugmaker GMP Failures
The European Medicines Agency (EMA) is stressing the need for timely, coordinated communications between EU member states when one state learns of a drugmaker’s noncompliance with good manufacturing practices (GMPs) from a non-EU country’s regulator or from an international organization, such as the World Health Organization.
The country that gets the notification of noncompliance should first determine the degree to which the issue affects drugs supplied to the EU so that the response can be based on the level of risk, according to a new EMA guideline, “Compilation of Community Procedures on Inspections and Exchange of Information.”
Each EU competent authority should have procedures for reviewing noncompliance information and determining whether it will impact products in the EU, the guideline states. If a potential health risk is identified, the competent authority in the member state that received the noncompliance notice should provide that information to all other authorities in the EU via teleconference in a timely manner.
International compliance is no longer simply a matter of playing by the same old rules. There’s been a dramatic increase in foreign inspections, and many countries are collaborating via joint inspections and confidentiality agreements that permit sharing of inspection results.
And in many countries, drug safety concerns are prompting new requirements. You either learn the new rules of the game, or cede the playing field to competitors.
Come for this valuable opportunity to hear FDA officials discuss regulatory plans and objectives — and ask questions you need answered; learn from device industry experts, consultants and other experts with actionable tips and strategies you can take straight back to the office; and network with other professionals who understand your challenges; share war stories and insights over a drink. Register Today.Read More
The FDA's new enforcement plan makes one thing clear: Developing a successful CAPA program has never been more important. But creating an FDA-proof CAPA isn’t easy. If only you could pick the brain of someone who is coping successfully with CAPA — the best and the brightest, an industry leader who has devised programs, procedures and solutions that have put companies out in front with the FDA. Well, you can. Register today.Read More
The FDA’s cadre of freshly trained inspectors — many of whom come directly from industry — and increased focus on specialized inspections are making it harder than ever to predict the outcome of your next FDA inspection. Unless, of course, you have Surviving an FDA Inspection at your fingertips. If you could spend less than $400 to get your drug manufacturing facility fully prepared to face a tough inspection by the FDA, would you even hesitate? ... Of course not!